ABSTRACT ABSTRACT BACKGROUND BACKGROUND METHODS METHODS
Methods:
Patients in this double-blind, acute portion of an extended, multicenter trial were randomized to approximately 12 weeks of atomoxetine treatment (n=87) or placebo (n=89). Patients met DSM-IV criteria for both ADHD and anxiety disorder (generalized anxiety, separation anxiety, or social phobia). ADHD RS and PARS total scores were analyzed using ANCOVA (LOCF) . Patients who responded during a placebo lead-in period were excluded from ADHD RS and PARS (total scores) analyses.
Results: Mean ADHD RS Total score improved significantly from baseline to endpoint for the atomoxetine group (n=55; -10.5, SD 10.6) relative to placebo (n=58; -1.4, SD 8.3; p<.001). Mean PARS total score also improved significantly from baseline to endpoint for the atomoxetine group (n=55; -5.5, SD 4.8) relative to placebo (n=58; -3.2, SD 5.0; p=.011).
Conclusion:
Results suggest atomoxetine is efficacious and well tolerated in pediatric patients with ADHD and comorbid anxiety.
Attention-deficit/hyperactivity disorder (ADHD)
Affects 3% to 7% of school-aged children in the United States (APA, 2000) .
Characterized by inattention and/or hyperactivity and impulsivity
ADHD and Comorbid Anxiety
Recent research indicates a 25% to 50% comorbidity of anxiety disorders with ADHD (Bird et al., 1993; Biederman et al., 1991) 
Atomoxetine
Atomoxetine is a potent inhibitor of the presynaptic norepinephrine transporter and is the first nonstimulant approved for ADHD treatment in children, adolescents, and adults.
The efficacy of atomoxetine for treating ADHD has been demonstrated in children and adolescents when administered once daily (Kelsey et al., 2004; Michelson et al., 2002) or twice daily (Michelson et al., 2001; Spencer et al., 2002) .
The efficacy of atomoxetine in pediatric patients with ADHD and comorbid anxiety is not known.
OBJECTIVE OBJECTIVE
This study compared atomoxetine to placebo in treating pediatric patients (children and adolescents) with ADHD and comorbid anxiety.
Patients
Children and adolescents, 8-17 years of age Met DSM-IV criteria for both ADHD and anxiety disorder (generalized anxiety, separation anxiety, or social phobia)
Had an ADHD symptom severity score at least 1.5 standard deviations above age and gender norms as assessed by the ADHD Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHD RS) (DuPaul et al., 1998; Faries et al., 2001 ) for the total score or either of the inattentive or the hyperactive/impulsive subscales
Study Design
Randomized, double-blind, placebo controlled, multicenter trial Patients randomized to approximately 12 weeks of atomoxetine or placebo
The target atomoxetine dose (1.2 mg/kg/day) could be increased to 1.8 mg/kg/day for patients not responding adequately All daily doses were split and administered BID *For subjects randomized to atomoxetine, the site personnel and subjects were blind to the timing and duration of placebo treatment. Only data from periods I and II are presented here.
Primary Efficacy Measures

ADHD-RS (18 items corresponding to the DSM-IV diagnostic symptoms of ADHD)
Pediatric Anxiety Rating Scale (PARS; an interview-based scale used to rate the severity of anxiety symptoms)
Secondary Efficacy Measure
Multidimensional Anxiety Scale for Children (MASC)
Statistical Analyses
ADHD RS and PARS total scores were analyzed using analysis of covariance (last observation carried forward)
Fisher's exact test was used for categorical analyses
The statistical analysis plan pre-specified that patients who responded during a placebo lead-in period would be excluded from the co-primary analyses (ADHD RS and PARS) 
Patient Demographics
